Zai Lab to present Phase 1/1b healthy-volunteer data for atopic disease antibody ZL-1503 at ACAAI 2026

By Public Technologies
  • Zai Lab flagged first clinical data for ZL-1503, a bispecific antibody for atopic diseases, from its Phase 1/1b healthy-volunteer trial.
  • Results have not been presented yet; the initial readout is scheduled for the ACAAI 2026 meeting on Nov. 13.
  • The update will cover how the drug behaved in the body, early biomarker effects, and initial safety and immunogenicity observations.
  • Zai Lab positioned the program as a potentially longer-acting approach aimed at reducing itch and inflammation in IL-13- and IL-31-driven conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610140700BIZWIRE_USPR_____20261014_BW931547) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.